The prophylaxis of nonindustrial urothelial tumours.
Present knowledge concerning carcinogenesis and the natural history of urothelial tumours precludes firm conclusions relative to nonindustrial prophylaxis. However, a number of measures are consistent with current data and may be instituted for those patients with a demonstrated propensity to urothelial tumours. Their acceptability is based on the lack of associated toxicity for the patient. These measures include the elimination of significant infection, cigarettes, artificial sweeteners, analgesic abuse and coffee, the administration of vitamins C and B(6), and in selected cases, the use of thiotepa. It is emphasized that the merit of these steps in altering the natural history of urothelial tumours is uncertain.
D000700:Analgesics; D001205:Ascorbic Acid / Q000008:administration & dosage / Q000627:therapeutic use; D003069:Coffee; D005260:Female; D006801:Humans; D008297:Male; D010212:Papilloma / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D011736:Pyridoxine / Q000627:therapeutic use; D012737:Sex Factors; D012907:Smoking; D013549:Sweetening Agents; D013852:Thiotepa / Q000008:administration & dosage / Q000627:therapeutic use; D014525:Urethral Stricture / Q000150:complications; D001749:Urinary Bladder Neoplasms / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*; D014552:Urinary Tract Infections / Q000150:complications; D014555:Urination Disorders / Q000150:complications
D000700:Analgesics; D003069:Coffee; D013549:Sweetening Agents; D013852:Thiotepa; D011736:Pyridoxine; D001205:Ascorbic Acid